PDF herunterladen
Geburtshilfe Frauenheilkd 2012; 72(10): R47-R62
DOI: 10.1055/s-0032-1327778
GebFra-Weiterbildung | Refresher
Georg Thieme Verlag KG Stuttgart · New York

Onkologische Therapien und Haarverlust

N. Hüttner
1   Frauenklinik des Universitätsklinikums Erlangen
,
C. R. Loehberg
1   Frauenklinik des Universitätsklinikums Erlangen
,
M. P. Lux
1   Frauenklinik des Universitätsklinikums Erlangen
,
M. W. Beckmann
1   Frauenklinik des Universitätsklinikums Erlangen
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
31. Oktober 2012 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Für den therapiebedingten Haarverlust existieren bisher keine effektiven Präventions- und Therapiemöglichkeiten. Gerade beim Haarverlust unter Chemotherapie, der sicherlich den schwerwiegendsten unter allen Therapien darstellt, sind zwar verschiedene Ansätze vorhanden, jedoch gibt es bisher noch keine Erfolg versprechende Maßnahme. Den ältesten und erprobtesten Ansatz stellt das Scalp-Cooling dar, welcher aber einen enormen technischen Aufwand sowie einige Risiken birgt.

Medikamentöse Therapien stehen nur in sehr limitiertem Maße zur Verfügung und zeigen bisher keinen durchschlagenden Erfolg. Am häufigsten werden Minoxidil und östrogenhaltige Lösungen angewendet, die jedoch die Alopezie nicht verhindern, sondern nur verkürzen können. Hormonhaltige Therapien sind allerdings bei hormonrezeptorpositiven Karzinomen kritisch zu sehen.

Die wichtigsten Punkte bei fehlenden Therapiemöglichkeiten zum Schutz vor Haarverlust sind die Aufklärung der Patientin und die Vermittlung von Bewältigungsstrategien.

 

  • Literatur

  • 1 McGarvey EL, Leon-Verdin M, Baum L et al. An evavluation of a computer imaging program to prepare women for chemotherapy-related alopecia. Psycho-Oncology 2010; 19: 756-766
    PubMedGoogle Scholar
  • 2 Mols F, van den Hurk CJ, Vingerhoets JJM et al. Scalp cooling to prevent chemotherapy-induced hair loss: practical and clinical considerations. Support Care Cancer 2009; 17: 181-189
    CrossrefPubMedGoogle Scholar
  • 3 Lemieux J, Maunsell E, Provencher L. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psycho-Oncology 2008; 17: 317-328
    PubMedGoogle Scholar
  • 4 Batchelor D. Hair and cancer chemotherapy: consequences and nursing care – a literature study. Eur J Cancer Care (Engl ) 2001; 10: 147-163
    CrossrefPubMedGoogle Scholar
  • 5 McElwee KJ, Shapiro J. Promising therapies for treating and/or preventing androgenic alopecia. Skin Therapy Lett 2012; 17: 1-4
    PubMedGoogle Scholar
  • 6 McGarvey EL, Baum LD, Pinkerton RC et al. Psychological sequelae and alopecia among women with cancer. Cancer Pract 2001; 9: 283-289
    CrossrefPubMedGoogle Scholar
  • 7 Roe H. Chemotherapy-induced alopecia: advice and support for hair loss. Br J Nurs 2011; 20: 4-11
    PubMedGoogle Scholar
  • 8 Trueb RM. Chemotherapy-induced alopecia. Curr Opin Support Palliat Care 2010; 4: 281-284
    CrossrefPubMedGoogle Scholar
  • 9 Wang J, Lu Z, Au JL. Protection against chemotherapy-induced alopecia. Pharm Res 2006; 23: 2505-2514
    CrossrefPubMedGoogle Scholar
  • 10 Chon SY, Champion RW, Geddes ER et al. Chemotherapy-induced alopecia. J Am Acad Dermatol 2011; 67: e37-e47
    PubMedGoogle Scholar
  • 11 Trueb RM. Chemotherapy-induced hair loss. Skin Therapy Lett 2010; 15: 5-7
    PubMedGoogle Scholar
  • 12 Alonso E, Fuchs E. The hair cycle. J Cell Sci 2006; 119: 391-393
    CrossrefPubMedGoogle Scholar
  • 13 Ohnemus U, Uenalan M, Inzunza J et al. The hair follicle as an estrogen target and source. Endocr Rev 2006; 27: 677-706
    CrossrefPubMedGoogle Scholar
  • 14 Stenn KS, Paus R. Controls of hair follicle cycling. Physiol Rev 2001; 81: 449-494
    PubMedGoogle Scholar
  • 15 Röcken M et al. Taschenatlas Dermatologie. Stuttgart: Thieme Verlag; 2010: 11
    Google Scholar
  • 16 Sterry W et al. Kurzlehrbuch Dermatologie. Stuttgart: Thieme Verlag; 2011: 243
    Google Scholar
  • 17 Otomo S. Hair growth effect of minoxidil. Nihon Yakurigaku Zasshi 2002; 119: 167-174
    CrossrefPubMedGoogle Scholar
  • 18 Botchkarev VA. Molecular mechanisms of chemotherapy-induced hair loss. J Investig Dermatol Symp Proc 2003; 8: 72-75
    CrossrefPubMedGoogle Scholar
  • 19 Paus R. Principles of hair cycle control. J Dermatol 1998; 25: 793-802
    PubMedGoogle Scholar
  • 20 Yeager CE, Olsen EA. Treatment of chemotherapy-induced alopecia. Dermatol Ther 2011; 24: 432-442
    CrossrefPubMedGoogle Scholar
  • 21 Tallon B, Blanchard E, Goldberg LJ. Permanent chemotherapy-induced alopecia: case report and review of the literature. J Am Acad Dermatol 2009; 10: 333-336
    PubMedGoogle Scholar
  • 22 Van den Hurk CJ, Mols F, Vingerhoets JJM et al. Impact of alopecia and scalp cooling on the well-being of breast cancer patients. Psycho-Oncology 2010; 19: 701-709
    PubMedGoogle Scholar
  • 23 Imanishi H, Tsuruta D, Tateishi C et al. Laminin-511, inducer of hair-growth, is down-regulated and its suppressor in hair growth, laminin-322 up-regulated in chemotherapy-induced alopecia. J Dermatol Sci 2010; 58: 43-54
    CrossrefPubMedGoogle Scholar
  • 24 Hesketh PJ, Batchelor D, Golant M et al. Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer 2004; 12: 543-549
    PubMedGoogle Scholar
  • 25 Im Internet: http://www.fachinfo.de Stand: 17.5.2012
    PubMed
  • 26 Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. 2012 Im Internet: http://www.krebsgesellschaft.de/download/S3_Brustkrebs_Update_2012_OL_Langversion.pdf Stand: 17.5.2012
    PubMedGoogle Scholar
  • 27 Gateley CA, Bundred NJ. Alopecia and breast disease. BMJ 1997; 314 (7079) 481
    PubMedGoogle Scholar
  • 28 Jamin C. Androgenetic alopecia. Ann Dermatol Venereol 2002; 129 (5 Pt 2) 801-803
    PubMedGoogle Scholar
  • 29 Li W, Li C, Lu Z. Vascular endothelial growth factor and its receptors my be one mechanism for androgenetic alopecia. Med Hypotheses 2009; 72: 366-367
    CrossrefPubMedGoogle Scholar
  • 30 Yano K, Brown LF, Detmar M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest 2001; 107: 409-417
    CrossrefPubMedGoogle Scholar
  • 31 Conrad F, Paus R. Estrogens and the hair follicle. JDDG 2004; 2: 412-423
    CrossrefPubMedGoogle Scholar
  • 32 Ehmann LM, Heinemann V, Wollenberg A. Neue Tyrosinkinase- und EFGR-Inhibitoren in der Tumortherapie. Herz und Haut als wichtige Schädigungsorgane. Teil B: Haut. Internist 2011; 52: 1359-1364
    CrossrefPubMedGoogle Scholar
  • 33 Boehm S, Rothermundt C, Hess D et al. Antiangiogenic drugs in oncology: a focus on drug safety and the elderly – a mini review. Gerontology 2010; 56: 303-309
    CrossrefPubMedGoogle Scholar
  • 34 Molina MA, Codony-Servat J, Albanell J et al. Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res 2001; 61: 4744-4749
    PubMedGoogle Scholar
  • 35 Baselga J, Cortés J, Kim SB et al. Pertuzumab plus Trastuzumab plus Docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-119
    CrossrefPubMedGoogle Scholar
  • 36 Mokbel K, Hassanally D. From HER2 to herceptin. Curr Med Res Opin 2001; 17: 51-59
    PubMedGoogle Scholar
  • 37 Zander T, Hallek M. Thyrosinkinaseinhibitoren in der Onkologie. Internist 2011; 52: 595-600
    CrossrefPubMedGoogle Scholar
  • 38 Rosman IS, Anadkat MJ. Tufted hair folliculitis in a woman treated with trastuzumab. Target Oncol 2010; 5: 295-296
    CrossrefPubMedGoogle Scholar
  • 39 Scheuer W, Friess T, Burtscher H et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009; 69: 9330-9336
    CrossrefPubMedGoogle Scholar
  • 40 Franklin MC, Kendall DC, Vajdos FF et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 5: 317-328
    CrossrefPubMedGoogle Scholar
  • 41 Im Internet: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm307592.htm Stand: 17.5.2012
    PubMed
  • 42 Im Internet: http://www.ema.europa.eu Stand: 17.5.2012
    PubMed
  • 43 Affara NI, Trempus CS, Schanbacher BL et al. Activation of Akt and mTOR in CD34+/K15+keratinocyte stem cells and skin tumors during multi-stage mouse skin carcinogenesis. Anticancer Res 2006; 26: 2805-2820
    PubMedGoogle Scholar
  • 44 Perez EA, Spano JP. Current and emerging targeted therapies for metastatic breast cancer. Cancer 2012; 118: 3014-3025
    CrossrefPubMedGoogle Scholar
  • 45 Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366: 520-529
    CrossrefPubMedGoogle Scholar
  • 46 Lee WJ, Lee JL, Chang SE et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. BJD 2009; 161: 1045-1051
    CrossrefPubMedGoogle Scholar
  • 47 Anderson JE, Hunt JM, Smith IE. Prevention of doxorubicin-induced alopecia by scalp cooling in patients with advanced breast cancer. Br Med J (Clin Res Fd) 1981; 282: 423-424
    CrossrefPubMedGoogle Scholar
  • 48 Grevelman EG, Breed WPM. Prevention of chemotherapy-induced hair loss by scalp cooling. Ann Oncol 2005; 16: 352-358
    CrossrefPubMedGoogle Scholar
  • 49 Hussein AM. Chemotherapy-induced alopecia: new developments. South Med J 1993; 86: 489-496
    CrossrefPubMedGoogle Scholar
  • 50 Poder TG, He J, Lemieux R. Effectiveness of scalp cooling in chemotherapy. Bull Cancer 2011; 98: 1119-1129
    PubMedGoogle Scholar
  • 51 Van den Hurk CJ, Peerbooms M, Van de Poll-Franse LV et al. Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients – results of the Dutch Scalp Cooling Registry. Acta Oncol 2012; 51: 497-504
    CrossrefPubMedGoogle Scholar
  • 52 Auvinen PK, Mähönen UA, Soininen KM et al. The effectiveness of a scalp cooling cap in preventing chemotherapy-induced alopecia. Tumori 2010; 96: 271-275
    PubMedGoogle Scholar
  • 53 Lemieux J, Amireault C, Provencher L et al. Incidence of scalp metastase in breast cancer: a retrospective cohort study in women who were offered scalp cooling. Breast Cancer Res Treat 2009; 118: 547-552
    CrossrefPubMedGoogle Scholar
  • 54 Van de Sande MA, van den Hurk CJ, Breed WP et al. Allow scalp cooling during adjuvant chemotherapy in patients with breast cancer; scalp metastases rarely occur. Ned Tijdschr Geneeskd 2010; 154: A21-A34
    PubMedGoogle Scholar
  • 55 Lachgar S, Charveron M, Gall Y et al. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermatol 1998; 138: 407-411
    CrossrefPubMedGoogle Scholar
  • 56 Rossi A, Cantisani C, Melis L et al. Minoxidil use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Discov 2012; 6: 130-136
    CrossrefPubMedGoogle Scholar
  • 57 Chen G, Baechle A, Nevins TD et al. Protection against cyclophosphamid-induced alopecia and inhibition of mammary tumor growth by topical 1,25-Dihyroxyvitamin D3 in mice. Int J Cancer 1998; 75: 303-309
    CrossrefPubMedGoogle Scholar
  • 58 Peters EMJ, Foitzik K, Paus R et al. A new strategy for modulating chemotherapy-induced alopecia, using PTH/PTHrP receptor agonist and antagonist. J Invest Dermatol 2001; 117: 173-178
    CrossrefPubMedGoogle Scholar
  • 59 Katikaneni R, Ponnapakkam T, Suda H et al. Treatment for chemotherapy-induced alopecia in mice using parathyroid hormone agonists and antagonists linked to a collagen binding domain. Int J Cancer 2011; 131: E813-E821
    PubMedGoogle Scholar
  • 60 Münstedt K, Manthey N, Sachsse S et al. Changes in self-concept and body image during alopecia induced cancer chemotherapy. Support Care Cancer 1997; 5: 139-143
    CrossrefPubMedGoogle Scholar
  • 61 World Health Organization. WHO Handbook for reporting results of cancer treatment. Geneva: World Health Organization; 1979. Im Internet: http://whqlibdoc.who.int/offset/WHO_OFFSET_48.pdf Stand 17.5.2012
    Google Scholar
  • 62 NCI-CTAE Version 4.0. Im Internet: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14.xls Stand 21.9.2012
    PubMedGoogle Scholar